Limits...
Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.

Zhou J, Ye Y, Zeng S, Zhou Y, Mao Z, Song X, Ying B, Lu X, Jiang H, Wang L - PLoS ONE (2013)

Bottom Line: Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups.Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P25-P75): 45.02%(35.12%-54.22%)] than in essential thrombocythemia (ET) patients [median(P25-P75): 28.23%(17.77%-41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = -0.051, p = 0.452).Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

ABSTRACT

Background: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients' hemogram variation remains not clear.

Methods: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR).

Results: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P25-P75): 45.02%(35.12%-54.22%)] than in essential thrombocythemia (ET) patients [median(P25-P75): 28.23%(17.77%-41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = -0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts.

Conclusions: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.

Show MeSH

Related in: MedlinePlus

Trends of JAK2 V617F mutation rate (a) and JAK2 V617F mutant allele burden (b) variation in groups classified by blood cell counts.*The number outside the parentheses presented RBC count of males, while the number inside the parentheses presented RBC count of females, owing to different reference range of RBC count in males and females. The vertical axis represents JAK2 V617F mutation rate (a) and the median of JAK2 V617F mutant allele burden (b) in groups classified by blood cell counts. Median of JAK2 V617F mutant allele burden in the group which was characterized by WBC counts <4.0×109/L was not shown in the figure, since only one patient was included into this group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585181&req=5

pone-0057856-g001: Trends of JAK2 V617F mutation rate (a) and JAK2 V617F mutant allele burden (b) variation in groups classified by blood cell counts.*The number outside the parentheses presented RBC count of males, while the number inside the parentheses presented RBC count of females, owing to different reference range of RBC count in males and females. The vertical axis represents JAK2 V617F mutation rate (a) and the median of JAK2 V617F mutant allele burden (b) in groups classified by blood cell counts. Median of JAK2 V617F mutant allele burden in the group which was characterized by WBC counts <4.0×109/L was not shown in the figure, since only one patient was included into this group.

Mentions: Patients were categorized into four groups by RBC counts (×1012/L): <4.0(<3.5), 4.0–5.5(3.5–5.0), 5.5–6.5(5.0–6.0), >6.5(>6.0). Owing to the different reference range of RBC count in males and females, RBC count of males and females were presented separately, the former is outside the parentheses and the latter is inside the parentheses in Table 2. JAK2 V617F mutation rates in the four groups were 37.14%, 43.95%, 82.00%, 96.61%, respectively, and the rates showed significant difference assessed by chi-square test. It was found that the p values were close to zero between any two neighboring groups, suggesting that JAK2 V617F mutation rate was increasing progressively with the increase of RBC count, as shown in Figure 1a. Further analysis was performed in ET patients, and a similar trend was observed, as shown in Table 2.


Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.

Zhou J, Ye Y, Zeng S, Zhou Y, Mao Z, Song X, Ying B, Lu X, Jiang H, Wang L - PLoS ONE (2013)

Trends of JAK2 V617F mutation rate (a) and JAK2 V617F mutant allele burden (b) variation in groups classified by blood cell counts.*The number outside the parentheses presented RBC count of males, while the number inside the parentheses presented RBC count of females, owing to different reference range of RBC count in males and females. The vertical axis represents JAK2 V617F mutation rate (a) and the median of JAK2 V617F mutant allele burden (b) in groups classified by blood cell counts. Median of JAK2 V617F mutant allele burden in the group which was characterized by WBC counts <4.0×109/L was not shown in the figure, since only one patient was included into this group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585181&req=5

pone-0057856-g001: Trends of JAK2 V617F mutation rate (a) and JAK2 V617F mutant allele burden (b) variation in groups classified by blood cell counts.*The number outside the parentheses presented RBC count of males, while the number inside the parentheses presented RBC count of females, owing to different reference range of RBC count in males and females. The vertical axis represents JAK2 V617F mutation rate (a) and the median of JAK2 V617F mutant allele burden (b) in groups classified by blood cell counts. Median of JAK2 V617F mutant allele burden in the group which was characterized by WBC counts <4.0×109/L was not shown in the figure, since only one patient was included into this group.
Mentions: Patients were categorized into four groups by RBC counts (×1012/L): <4.0(<3.5), 4.0–5.5(3.5–5.0), 5.5–6.5(5.0–6.0), >6.5(>6.0). Owing to the different reference range of RBC count in males and females, RBC count of males and females were presented separately, the former is outside the parentheses and the latter is inside the parentheses in Table 2. JAK2 V617F mutation rates in the four groups were 37.14%, 43.95%, 82.00%, 96.61%, respectively, and the rates showed significant difference assessed by chi-square test. It was found that the p values were close to zero between any two neighboring groups, suggesting that JAK2 V617F mutation rate was increasing progressively with the increase of RBC count, as shown in Figure 1a. Further analysis was performed in ET patients, and a similar trend was observed, as shown in Table 2.

Bottom Line: Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups.Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P25-P75): 45.02%(35.12%-54.22%)] than in essential thrombocythemia (ET) patients [median(P25-P75): 28.23%(17.77%-41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = -0.051, p = 0.452).Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

ABSTRACT

Background: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients' hemogram variation remains not clear.

Methods: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR).

Results: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P25-P75): 45.02%(35.12%-54.22%)] than in essential thrombocythemia (ET) patients [median(P25-P75): 28.23%(17.77%-41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = -0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts.

Conclusions: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.

Show MeSH
Related in: MedlinePlus